Serum calprotectin elevation and interferon-α-induced neutrophil priming in macrophage activation syndrome associated with systemic lupus erythematosus: Clinical and experimental insights
Modern Rheumatology · 2026
DOI: 10.1093/mr/roag012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Yohei Hosokawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Macrophage Activation Syndrome, Lupus Erythematosus, Systemic, Leukocyte L1 Antigen Complex, Interferon-alpha. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: JSPS KAKENHI, Tsuchiya Memorial Medical Foundation.
Abstract (Originalsprache)
Objectives
To clarify the diagnostic utility of serum calprotectin and gene expression in interferon (IFN)-α-activated neutrophils in macrophage activation syndrome (MAS) in patients with systemic lupus erythematosus (SLE).
Methods
This single-centre, cross-sectional study analysed serum calprotectin levels in 47 patients with SLE (including eight with MAS) and 7 patients with adult-onset Still’s disease (AOSD) complicated with MAS as a reference population. In neutrophil-based experiments, mRNA expression levels of S100A8 and S100A9 were measured following stimulation with IFN-α or interleukin (IL)-1β.
Results
Serum calprotectin levels were significantly elevated in patients with SLE-MAS compared to those with SLE without MAS and comparable to those in patients with AOSD-MAS. Calprotectin levels correlated with serum ferritin levels (rs = 0.49, P = .004), but not with anti-dsDNA antibodies or complement levels. At a cut-off value of 9184.4 ng/ml, serum calprotectin demonstrated sensitivity of 62.5% and specificity of 94.9% for identifying MAS. Recombinant IFN-α2a induced a dose-dependent increase in S100A8 and S100A9 expression in neutrophils, whereas recombinant interleukin-1β had no effect. Pre-treatment with an anti-IFN-α2 neutralising antibody effectively suppressed the IFN-α2a-induced expression of S100A8 and S100A9.
Conclusions
Serum calprotectin, upregulated by IFN-α, may serve as a useful biomarker for diagnosing MAS in SLE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
- Division of Laboratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.
ORCID-Profile: Yohei Hosokawa, Yusuke Yoshida, Sho Mokuda, Naoya Oka, Hiroki Kobayashi, Genki Kidoguchi, Michinori Ishitoku, Tomohiro Sugimoto, Shintaro Hirata
Förderung
- JSPS KAKENHI
- Tsuchiya Memorial Medical Foundation
Zitieren
APA
Hosokawa, Y., Yoshida, Y., Mokuda, S., Oka, N., Kobayashi, H., Kidoguchi, G., Ishitoku, M., Sugimoto, T., & Hirata, S. (2026). Serum calprotectin elevation and interferon-α-induced neutrophil priming in macrophage activation syndrome associated with systemic lupus erythematosus: Clinical and experimental insights. Modern Rheumatology. https://doi.org/10.1093/mr/roag012
Vancouver
Hosokawa Y, Yoshida Y, Mokuda S, Oka N, Kobayashi H, Kidoguchi G, et al. Serum calprotectin elevation and interferon-α-induced neutrophil priming in macrophage activation syndrome associated with systemic lupus erythematosus: Clinical and experimental insights. Modern Rheumatology. 2026. doi:10.1093/mr/roag012
BibTeX
@article{Hosokawa2026,
author = {Hosokawa, Yohei and Yoshida, Yusuke and Mokuda, Sho and Oka, Naoya and Kobayashi, Hiroki and Kidoguchi, Genki and Ishitoku, Michinori and Sugimoto, Tomohiro and Hirata, Shintaro},
title = {Serum calprotectin elevation and interferon-α-induced neutrophil priming in macrophage activation syndrome associated with systemic lupus erythematosus: Clinical and experimental insights},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roag012}
}
EUVIMED